Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism

Rheumatism Clinical Trial

— RICOVID19  

Official title:

Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism According to a Management Strategy in the Rheumatology Department of Limoges University Hospital

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04723407
• Other study ID #: 87RI20_0062 /RICOVID19
• Status: Not yet recruiting
• Start date: February 1, 2021
• Est. completion date: March 1, 2022

Study information

• Verified date: January 2021
• Source: University Hospital, Limoges
• Contact: Philippe BERTIN, MD
• Phone: 0555056871
• Email: philippe.bertin[@]chu-limoges.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients with chronic inflammatory rheumatism (RIC) or autoimmune diseases, rheumatoid arthritis and spondyloarthritis, are regularly monitored in consultation as part of a "treat to target" strategy with rapid adaptation of treatments to the activity of their disease. according to French recommendations.

They are treated with immunosuppressive drugs: disease-modifying treatments with very often methotrexate, associated with biotherapies or targeted therapies (JAK inhibitors) They can also be treated transiently or over the long term with corticosteroids. These treatments expose them to greater infectious risks, especially with regard to COVID19.

The objective is on the one hand to assess the impact of the Covid 19 pandemic on general state of health of these patients and the evolution of their disease and on the other hand to prioritize the optimal care of these patients by including in the context of maintaining the pandemic reduction rules, modern telemedicine technologies.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 950
• Est. completion date: March 1, 2022
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All patients with chronic inflammatory rheumatism followed in the rheumatology department of the CHU de Limoges.

Exclusion Criteria:

Patients who object to the use of their data.

Related Conditions & MeSH terms

• Collagen Diseases
• Rheumatic Diseases
• Rheumatic Fever
• Rheumatism

Intervention

Other:
• questionnaires
Questionnaire completion

Locations

Country	Name	City	State
France	Département de Rhumatologie	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	post-traumatic stress	Presence or absence of post-traumatic stress disorder due to the COVID19 pandemic assessed by the Post-traumatic stress disorder Check-list version DSM-5 (PCL-5)	Day 1